The DOI matches its Crossref record; 128 of the 130 references it cites were found in a registry or an index; 51 of the 84 sources its claims cite were checked for support.
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Open accessAbstract
This review explores radiopharmaceuticals, targeted delivery, theranostics, imaging and therapeutic innovation, with attention to safety considerations.
Overview
CoChat Summary
## TL;DR
This is a narrative review of radiopharmaceuticals, covering how radiolabelling, targeted delivery, imaging, theranostics, safety, nanoparticles, and future AI-enabled approaches are reshaping precision medicine. It argues that radiopharmaceuticals can improve diagnostic accuracy and treatment specificity while reducing off-target effects, with case examples showing survival benefits in several cancers.
## Key findings
- The review highlights three targeted delivery strategies: passive targeting via the enhanced permeability and retention effect, active ligand-receptor targeting, and stimulus-responsive release systems.
- In the VISION phase III trial, ^177Lu-PSMA-617 plus standard care in PSMA-positive mCRPC increased median overall survival from 11.3 to 15.3 months and median radiographic progression-free survival from 3.4 to 8.7 months.
- In the ALSYMPCA phase III trial, ^223Ra-dichloride in castration-resistant prostate cancer with bone metastases increased median overall survival from 11.3 to 14.9 months and median time to first symptomatic skeletal event from 9.8 to 15.6 months.
- In a phase II neuroblastoma trial, ^131I-MIBG with chemotherapy and stem cell rescue improved 3-year event-free survival from 48% to 61% and 3-year overall survival from 59% to 74%.
- The paper emphasizes that radiopharmaceuticals are moving toward theranostics, where the same agent supports both imaging and therapy, and that AI may improve image analysis, staging, and treatment planning.
## Methods
- Narrative review of the radiopharmaceuticals field, organized around targeted drug delivery, imaging and theranostics, safety, next-generation formulations, case studies, and future directions.
- Uses published examples and clinical trials as illustrative case studies, including PSMA-targeted therapy in prostate cancer, PRRT in neuroendocrine tumors, bone-targeted agents, and neuroblastoma radiopharmaceuticals.
- Main analysis is qualitative and descriptive; the paper synthesizes prior literature rather than reporting a new experimental dataset or statistical model.
## Limitations
- The paper does not state formal limitations explicitly.
- Evident from the text: it is a broad narrative review, so its claims are largely synthesis-based rather than derived from a systematic review or original study.
- Evident from the text: many sections are highly general and descriptive, with limited critical comparison of opposing evidence or detailed methodological appraisal of the cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
43 Valid · 7 Not valid · 33 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The integration of radiopharmaceutical techniques with other diagnostic methods, such as the combination of PET and MRI, provides complementary anatomical and functional information, improving diagnostic accuracy in neurological disorders [44].”
§ Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation > Radiopharmaceuticals in imaging and theranostics > Role of imaging in advancements Radiopharmaceutical imaging plays a crucial role in advancing medicine, with diverse applications across various medical fields. In oncology, these specialized drugs help identify specific tumor markers, making it easier to locate and stage cancerous lesions [42]. This, in turn, enables the customization of targeted therapies and improves the monitoring of treatment effectiveness. In cardiology, radiopharmaceutical imaging is instrumental in assessing myocardial perfusion and function, leading to earlier detection of coronary artery disease, better risk evaluation, and enhanced patient outcomes [43]. The integration of radiopharmaceutical techniques with other diagnostic methods, such as the combination of PET and MRI, provides complementary anatomical and functional information, improving diagnostic accuracy in neurological disorders [44]. Beyond diagnosis, radiopharmaceutical imaging extends its influence into theranostics, where the same drug used for imaging also serves as a carrier for targeted radionuclide therapy. This emerging field holds promise for personalized treatment approaches tailored to patients' unique molecular profiles [45]. The intricate synergy between radiopharmaceutical development, imaging technology, and computational analysis has driven the creation of novel tracers and imaging protocols. As radiopharmaceutical chemistry evolves, producing compounds with enhanced specificity and longer half-lives, the potential for non-invasive imaging and therapy continues to grow [46]. In research, radiopharmaceutical imaging opens new avenues for investigating fundamental biological processes, providing valuable insights into disease mechanisms and treatment strategies. Additionally, it contributes to understanding drug pharmacokinetics and pharmacodynamics, facilitating drug development and optimization.
What the sources say
- Partly supportedcites [44] Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51(3):333–6. sourceExperimental — accuracy not yet measured
The Abstract says MRI’s soft-tissue contrast complements PET’s molecular information. In “Clinical Potential of PET/MRI” (page unavailable), the paper describes a brain-tumor case in which combining the images revealed disease extent that neither modality showed fully alone. It presents broader benefits for neurological disorders as expectations, rather than establishing a general improvement in diagnostic accuracy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Nanocarriers, including liposomes, micelles, polymers, dendrimers, and various nanoparticles, such as those made of gold, iron oxide, silica, or carbon, are being carefully designed to enhance their circulation time, biodistribution, and tumor penetration [19].”
§ Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation > Targeted drug delivery strategies > Passive targeting: enhanced permeability and retention
What the sources say
- Partly supportedcites [19] Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, Tong R, Miao YB, Cai L. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023;8(1):418. sourceExperimental — accuracy not yet measured
The Type of smart nanocarriers sections describe the listed carrier classes and designs that extend circulation or improve tumor targeting; the Target section also discusses nanoparticle accumulation at tumor sites. These passages do not establish improved penetration into tumor tissue. The supplied paraphrase adds “radiolabelled,” but the citing sentence does not; the paper discusses radiolabelling specifically for liposomes, not for every listed carrier. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Approved by the FDA in 2018 for treating gastroenteropancreatic neuroendocrine tumors, a phase III clinical trial demonstrated improved progression-free survival and overall response rates compared to standard therapy [21].”
§ Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation > Targeted drug delivery strategies > Active targeting: ligand-receptor strategies Active targeting is a strategic approach in which a ligand, such as an antibody, peptide, or small molecule, is attached to a radioactive molecule, like a radioisotope. This method is designed to deliver radiation therapy directly to cancer cells that express specific receptors, thereby enhancing therapeutic efficacy and minimizing the toxicity of radiopharmaceuticals. Several successful examples of radiopharmaceuticals utilizing active targeting include Lutetium-177 dotatate (Lutathera), which targets the somatostatin receptor overexpressed in neuroendocrine tumors. Approved by the FDA in 2018 for treating gastroenteropancreatic neuroendocrine tumors, a phase III clinical trial demonstrated improved progression-free survival and overall response rates compared to standard therapy [21]. Another example is Radium-223 dichloride (Xofigo), which targets the bone matrix, preferentially accumulating in bone metastases. FDA-approved in 2013 for metastatic castration-resistant prostate cancer, a phase III clinical trial revealed enhanced overall survival and delayed symptomatic skeletal events compared to placebo [22]. Iodine-131 tositumomab (Bexxar) targets the CD20 antigen expressed on B cells and B-cell lymphomas. Approved by the FDA in 2003 for relapsed or refractory non-Hodgkin lymphoma, a phase III clinical trial demonstrated improved overall response rates and duration of response compared to rituximab, another CD20-targeting antibody [23]. These examples showcase the effectiveness of active targeting in tailoring radiation therapy to specific cancer cells, marking a significant advancement in precision medicine.
What the sources say
- Partly supportedcites [21] Yang K, Li J, Cheng Y, Bai C. Evolving landscape of clinical trials in gastroenteropancreatic neuroendocrine neoplasms in the past two decades. Endocr Connect. 2023. https://doi.org/10.1530/EC-22-0441. sourceExperimental — accuracy not yet measured
The Introduction identifies peptide receptor radionuclide therapy as a treatment used to inhibit tumor growth, and the References list a phase 3 trial of 177Lu-Dotatate in midgut neuroendocrine tumors (page numbers unavailable). The paper does not report that trial’s progression-free survival or response-rate results versus standard therapy, or state the claimed 2018 FDA approval. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Diagnostic procedures like PET, SPECT, and scintigraphy utilize radiopharmaceuticals for early disease detection, leading to improved interventions [2].”
§ Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation > Introduction Radiopharmaceuticals serve as a crucial intersection of medicine, chemistry, and nuclear physics, playing a vital role in diagnostic imaging and targeted therapies. These compounds, meticulously engineered through the fusion of biologically active molecules and radioisotopes, offer non-invasive insights into molecular processes at cellular levels [1]. Diagnostic procedures like PET, SPECT, and scintigraphy utilize radiopharmaceuticals for early disease detection, leading to improved interventions [2]. Beyond diagnostics, radiopharmaceuticals are integral to targeted radionuclide therapy, a precise method of delivering radioactive payloads to diseased tissues. This approach enhances treatment efficacy while minimizing damage to healthy tissues, ultimately improving patient outcomes [3]. The integration of radiopharmaceuticals into therapeutic protocols reveals a captivating relationship of pharmacokinetics and biodistribution, governing their intricate journey within the human body. Understanding their absorption, distribution, metabolism, and excretion is crucial for shaping clinical protocols. Many studies have not only explored the mechanisms dictating radiopharmaceutical behavior but also unveiled the dynamic interplay between chemical composition, physiological context, and molecular recognition. Moreover, recent advancements in radiopharmaceutical research have introduced innovative strategies for enhancing their specificity and therapeutic effectiveness [4]. The development of novel targeting agents, improved radionuclide selection, and innovative delivery systems contribute to the evolving landscape of radiopharmaceutical applications [5]. In essence, the pharmacokinetics and biodistribution of radiopharmaceuticals provide a rich narrative on the canvas of human physiology, guiding practitioners and researchers to unlock the full potential of these marvels in healthcare. The continual refinement of these compounds and their applications promises even greater strides in the realms of diagnosis and targeted therapy, offering new avenues for improving patient care and outcomes.
What the sources say
- Partly supportedcites [2] Sun ZH, Rashmizal H, Xu L. Molecular imaging of plaques in coronary arteries with PET and SPECT. J Geriatr Cardiol JGC. 2014;11(3):259. doi:10.11909/j.issn.1671-5411.2014.03.005Experimental — accuracy not yet measured
The Summary and concluding remarks (page unavailable) says SPECT and PET use radiopharmaceuticals to identify high-risk coronary plaques, and that PET can detect early atherosclerotic changes. The paper describes PET and SPECT as scintigraphic techniques, but it does not establish that their use leads to improved interventions; it says further study is needed to determine whether molecular imaging can guide patient therapy. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Radiopharmaceutical therapy, often termed “radionuclide therapy,” capitalizes on the precise localization of radiotracers, emitting therapeutic radiation that selectively destroys or halts the growth of cancerous cells [48].”
§ Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation > Radiopharmaceuticals in imaging and theranostics > Theranostics: healing through imaging-guided therapies This innovative strategy harnesses the unique properties of radiopharmaceuticals, allowing for the simultaneous visualization and treatment of diseases at the molecular level. By utilizing radiotracers labelled with radioisotopes, clinicians can accurately identify specific biomarkers and assess the extent of disease progression through high-resolution imaging modalities such as PET and SPECT [47]. However, what sets radiopharmaceuticals theranostics apart is its transformative potential to go beyond diagnosis. The same radiotracers employed for imaging can be ingeniously tailored to deliver therapeutic payloads directly to diseased cells. This image-guided therapeutic approach ensures pinpoint accuracy in targeting malignant tissues while minimizing collateral damage to healthy organs. Radiopharmaceutical therapy, often termed “radionuclide therapy,” capitalizes on the precise localization of radiotracers, emitting therapeutic radiation that selectively destroys or halts the growth of cancerous cells [48]. This novel approach holds immense promise for refractory cancers and metastatic disease, where conventional treatments have shown limitations. The synergy between diagnostics and therapy in radiopharmaceuticals theranostics brings forth a new era of individualized medicine. Treatment regimens can be customized based on real-time imaging data, allowing clinicians to adapt and optimize therapies according to the patient’s response. This approach not only enhances treatment efficacy but also mitigates potential adverse effects, leading to improved patient outcomes and quality of life. In addition to oncology, radiopharmaceuticals theranostics demonstrate its versatility across various medical domains. In cardiology, it enables the assessment of myocardial perfusion and viability, aiding in the management of coronary artery disease [49]. Neurological applications encompass the diagnosis and monitoring of neurodegenerative disorders, with radiopharmaceuticals providing insights into neural function and degeneration patterns [50]. Beyond disease-oriented applications, radiopharmaceuticals theranostics plays a pivotal role in advancing our understanding of fundamental biological processes, offering a dynamic platform for pharmaceutical research and drug development. As we navigate the frontiers of modern medicine, radiopharmaceuticals theranostics emerges as a beacon of hope, illuminating the path toward more effective, personalized, and targeted therapeutic interventions. Its seamless integration of imaging and therapy, underpinned by precise radiotracer design and innovative instrumentation, holds the potential to reshape the landscape of medical practice, ultimately culminating in improved patient care and unprecedented medical breakthroughs [51].
What the sources say
- Supportedcites [48] Zukotynski K, Jadvar H, Capala J, Fahey F. Targeted radionuclide therapy: practical applications and future prospects: supplementary issue: biomarkers and their essential role in the development of personalised therapies (a). Biomarkers Cancer. 2016;8:31804. source
The Introduction defines targeted radionuclide therapy as therapy at the cellular or molecular level and says it delivers radiation directly to the targeted disease site. It also describes radiation-induced cancer-cell death, supporting the claim’s account of how the treatment works. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
64 more claims · 32 with their cited sources checked
Create a free account to see all 101 claims and every source verdict.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 8
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Research and clinical trials in this domain have surged, indicating the potential to minimize side effects and target minute cancer cell deposits throughout the body [113].”
Cited work 10.1016/j.pmatsci.2023.101209 · retracted 2023-12-01 · notice 10.1016/j.pmatsci.2023.101190 · this paper published 2024-01-05
Citations
Cites
1 retracted
Beygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32 · cited 1×
“Research and clinical trials in this domain have surged, indicating the potential to minimize side effects and target minute cancer cell deposits throughout the body [113].”
BackgroundRetractedLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · cited 1×
“The median over-all survival increased from 11.3 to 15.3 months, and the median radiographic progression-free survival extended from 3.4 to 8.7 months [86].”
BackgroundInfluentialMolecular imaging of cancer with positron emission tomography
Gambhir, S. S. (2002) · Nature Reviews Cancer · doi:10.1038/nrc882 · Cited by 1,656
Nanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy
Chen, G., Roy, I., Yang, C., & Prasad, P. N. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00148 · Cited by 1,499
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662 · cited 1×
“This emerging field holds promise for personalized treatment approaches tailored to patients’ unique molecular profiles [45].”
BackgroundGeneral mechanisms of metastasis
Woodhouse, E. C., Chuaqui, R. F., & Liotta, L. A. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1529::aid-cncr2>3.3.co;2-# · Cited by 609
Carbon nanotubes for delivery of small molecule drugs
Wong, B. S., Yoong, S. L., Jagusiak, A., Panczyk, T., Ho, H. K., Ang, W. H., & Pastorin, G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.005 · Cited by 585 · cited 1×
“…‑ Enhanced permeability and retention effect utiliza‑ Personalized treatment with controlled drug Combination therapy for synergistic effects [68] Imaging‑guided therapies Incorporation of radiotracers for real‑time monitor‑ ing ‑ Simultaneous imaging and therapy for real‑time Image‑guided…”
BackgroundTargeted Radionuclide Therapy of Human Tumors
Gudkov, S., Shilyagina, N., Vodeneev, V., & Zvyagin, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010033 · Cited by 456
PET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications
Pichler, B. J., Kolb, A., Nägele, T., & Schlemmer, H.-P. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.061853 · Cited by 418 · cited 1×
“The integration of radiopharmaceutical techniques with other diagnostic methods, such as the combination of PET and MRI, provides complementary anatomical and functional information, improving diagnostic accuracy in neurological disorders [44].”
Method
Research works printed but not linked: 1
- Sarkar PS. Safety, regulations, metrology and standards in neutron imaging. In: Kashyap YS, Aswal DK, Sarkar PS, editors. Neutron imaging: basics, techniques and applications. Singapore: Springer Singapore; 2022.
Cited by
Kiran, N. S., Yashaswini, C., Maheshwari, R., Bhattacharya, S., & Prajapati, B. G. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00008 · Cited by 73
Nanocellulose in targeted drug delivery: A review of modifications and synergistic applications
Babaei-Ghazvini, A., Patel, R., Vafakish, B., Yazdi, A. F. A., & Acharya, B. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135200 · Cited by 68
Mulat, M., Banicod, R. J. S., Tabassum, N., Javaid, A., Karthikeyan, A., Jeong, G., Kim, Y., Jung, W., & Khan, F. (2025) · Antibiotics · doi:10.3390/antibiotics14060555 · Cited by 80
Theranostics: Integrated Diagnostics and Therapy Using Nanomedicine
Singh, V. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_17 · Cited by 52
Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy
Varghese, T. P., John, A., & Mathew, J. (2024) · Precision Radiation Oncology · doi:10.1002/pro6.1239 · Cited by 40
Metadata
- Authors
- Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F.
- Affiliations
- Galgotias University (IN)
- Delhi Pharmaceutical Science and Research University (IN)
- Case Western Reserve University (US)
- Amity University Madhya Pradesh (IN)
- Corresponding author
- Srivastava, Shriyansh
- ORCID
- Venue
- European Journal of Medical Research
- Published
- 2024-01-05
- Volume
- 29
- Issue
- 1
- Pages
- 26-26
- ISSN
- 0949-2321 (ISSN-L)
- 2047-783X
- PMC
- PMC10768149
- OpenAlex
- W4390632397
- Semantic Scholar
- 875624cd6dcf87e578f7df14d948a53417531e79
- Cited by
- 144
- References
- 130
- Citations by year
- 2026: 36 · 2025: 64 · 2024: 44
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- European journal of medical research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- radiopharmaceuticals, targeted drug delivery, enhanced permeability and retention effect, ligand-receptor targeting, stimuli-responsive drug release, theranostics, diagnostic imaging, radiolabeled antibodies, peptide receptor radionuclide therapy, neuroendocrine tumors, bone metastasis, nanoparticle formulation, precision medicine, artificial intelligence, radionuclides
- MeSH terms
- Artificial Intelligence, Humans, Radiopharmaceuticals, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. https://app.cochat.ai/papers/10.1186/s40001-023-01627-0
- The paper
- Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024). Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. European Journal of Medical Research. https://doi.org/10.1186/s40001-023-01627-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.